Frequently asked questions.

No. Helveteq does not provide investment advice, portfolio management or distribution services. All information on this website is provided for informational purposes only.

No. Helveteq does not accept subscriptions or execute transactions. Investments can only be made via a bank or broker.

Helveteq AG acts as issuer and product manufacturer. Banks and brokers act as distributors and execution venues unless explicitly stated otherwise.

No. Helveteq does not provide regulatory, capital, tax or accounting advice. Institutions and investors must rely on their own advisers.

Helveteq issues:

• Exchange Traded Products (ETPs)
• Non-listed Exchange Traded Products (nETPs)
• Actively Managed Certificates (AMCs)

These can be structured across traditional and digital assets, private debt and real-estate-related exposures.

An Exchange Traded Product (ETP) is a fully collateralised bearer debt security listed on a regulated exchange and designed to replicate the performance of an underlying asset or strategy, subject to the product terms.

ETPs are listed on the SIX Swiss Exchange under a Base Prospectus approved by SIX Exchange Regulation. nETPs share the same legal and security framework — Swiss ISIN, Base Prospectus, full collateralisation — but are not exchange-listed. AMCs are actively managed certificates whose composition changes at the discretion of the asset manager; depending on the regulatory regime and target market, they may be issued without a prospectus.

Listed ETPs are issued under a Base Prospectus approved by SIX Exchange Regulation and admitted to trading on the SIX Swiss Exchange under the ARETP rules. Non-listed products (nETPs, AMCs) are structured under FinSA. Helveteq products are not collective investment schemes and are therefore outside the scope of CISA.

The Base Prospectus, Final Terms and Key Information Documents (KID) are published on the Helveteq website and linked from each product page.

Helveteq products are fully collateralised. The Collateral is held by an independent Custodian and pledged to an independent Security Agent for the benefit of investors. The specific arrangements are set out in the Base Prospectus and the relevant Final Terms.

Yes. Helveteq products are bearer debt securities and therefore subject to issuer risk. A fully collateralised structure mitigates this risk; it does not eliminate it.

On an Insolvency Event, the Security Agent enforces the Pledge over the Collateral on behalf of investors and applies the proceeds in accordance with the Priority of Payments set out in the Base Prospectus.

No. Helveteq products are not guaranteed and do not provide capital protection unless explicitly stated in the Final Terms of a specific product.

The Net Asset Value (NAV) is calculated according to the methodology set out in the Final Terms. For listed products, market prices may differ from NAV due to supply and demand on the exchange.

Liquidity depends on the product. Listed ETPs trade on the SIX Swiss Exchange with bid and offer prices maintained by a Market Maker. Non-listed products are redeemable on the terms set out in their Final Terms. Trading prices may differ from NAV.

Redemption features are set out in the applicable Final Terms. Early redemption is not guaranteed.

Product-related fees are disclosed in the Final Terms and product documentation. Additional fees may apply at the level of the investor's bank or broker.

Helveteq products are bought and sold through banks or brokers using the Swiss ISIN. Execution and suitability assessment are handled by the investor's bank or broker.

Each issuance involves regulated counterparties acting within their respective frameworks. The Custodian holds the Collateral. The Security Agent holds the Pledge for the benefit of investors. The Paying Agent operates settlement and clearing. For listed products, Authorized Participants — which may also act as Market Makers and liquidity providers — create and redeem Securities in the primary market and provide secondary-market liquidity. For non-listed products distributed to non-professional investors, an Authorized Offeror is appointed; for non-listed products restricted to professional investors, no Authorized Offeror is required.

Depending on the structure and applicable regulatory treatment, Helveteq products may be used by regulated financial institutions to transfer asset exposures and associated risks to investors. Any balance sheet or capital impact depends on the institution's internal policies and applicable regulations.

Helveteq does not assess investor suitability. Any suitability or appropriateness assessment is performed exclusively by the investor's bank or broker.

Where a product is subject to SFDR, the relevant pre-contractual and periodic disclosures are published with the product documentation. The applicable SFDR classification is stated in the Final Terms.

Helveteq does not handle end-investor money. End-investor KYC and AML screening are performed by the distributor bank under its own AMLA framework. The Paying Agent operates under FINMA and its own AMLA framework.

KYI is the due-diligence process Helveteq performs on each third-party provider and client (originators, asset managers, distribution partners). It is the issuer-side counterpart to KYC, which the distributor bank performs on the end-investor. The two are separate.

Tax reporting on subscriptions and redemptions is the responsibility of the distributor bank in accordance with applicable law and the relevant tax treaties.

About two weeks from signed terms to ISIN live, for a standard structure. Complex underlyings, multi-jurisdiction distribution or first-time onboarding can extend the timeline.

CHF 1 million is the minimum for an ETP listing on SIX under the ARETP rules. In practice, the economics work for both sides from CHF 2 to 3 million.

Setup and ongoing fees depend on the format, underlying and structure. We quote after the structuring discussion and KYI review.